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Abstract
The P2X7 plasma membrane receptor is an intriguing molecule that is endowed with the ability to kill cells, as well as to
activate many responses and even stimulate proliferation. Here, the authors give an overview on the multiplicity and
complexity of P2X7-mediated responses, discussing recent information on this receptor. Particular attention has been paid to
early and late signs of apoptosis and necrosis linked to activation of the receptor and to the emerging ﬁeld of P2X7 function
in carcinogenesis.
P2X7: From an elusive receptor to an ATP-gated
channel/pore
The P2X7 receptor (P2X7R) for extracellular ATP is
expressed by a variety of cell types as different as neurons,
macrophages, dendritic and microglial cells, ﬁbroblasts,
lymphocytes, and endothelial cells. At least a subpopula-
tion of human osteoblasts also express P2X7 [1]. Expres-
sion of the receptor has been demonstrated in human
ﬁbroblasts [2, 3] and epithelia from the human bladder [4,
5], human and rat uterus [6, 7], male genital organs of the
rats [8], human fetal keratinocytes [9] and mouse parotid
acinar and duct cells [10].
Although interest in this molecule has increased expo-
nentially since the late 1990s, initial observations on its
peculiar biochemical properties go back to the 1970s, when
Cockcroft and Gomperts reported that extracellular ATP
caused degranulation and striking morphological changes
in rat mast cells [11]. These authors also hypothesized that
cell responses triggered by ATP, such as histamine se-
cretion and phosphatidyl inositol formation, were due to
activation of an as yet unknown receptor (the FATP
receptor_) activated by the fully dissociated ATP form
(ATP
4j) [12]. Based on its intriguing ability to cause a
reversible permeabilization of the plasma membrane, this
receptor was also referred to as the Fpermeabilizing ATP
receptor_ later named P2Z [13]. P2Z was described not
only in rat mast cells but also in mouse macrophages [14,
15]. Following these early observations, the peculiar phar-
macological and biochemical properties of the P2Z re-
ceptor were recognized in many other cells such as human
macrophages, human B lymphocytes, mouse microglial
cells, mouse and human monocyte-derived dendritic cells.
The permeabilizing ATP receptor was cloned in 1996
from a rat brain library and named P2X7 for its homology
with the other P2X receptors [16]. P2X7 is a 595 AA pro-
tein with a predicted structure comprising two transmem-
brane domains and a bulky extracellular cysteine rich
region, with conserved lysine and glycine residues and
several potential N-linked glycosylation sites, followed by
a long stretch (from Phe
188 to Val
321) forming six putative
antiparallel b sheets. The amino and carboxyl-terminal
domains are both cytoplasmic. Similarities have been found
between the b sheets region and the catalytic domains of
class II aminoacylYtRNA synthetases [17]. These b sheets
are likely to include residues comprising the ATP-binding
site, since substitution of two aminoacids comprised in this
region, Lys
193 and Lys
311, completely abrogates ethidium
and barium uptake [18].
P2X7 is an ionotropic, ligand-gated, cation channel [19,
20]. Stimulation of the receptor with low ATP doses, re-
versibly opens a membrane channel permeable to small
cations (Na
+,C a
2+,K
+), while sustained stimulation with
higher ATP doses or repeated stimulation with sequential
ATP pulses, induces the formation of a pore permeable to
large molecular weight molecules such as choline (100 Da),
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[21Y24]. ATP generates in B and T lymphocytes a pore
with a smaller molecular cut-off of slightly over 300 Da
(ethidium is admitted, propidium is excluded) [25Y27].
Alkalinization of the medium or removal of Mg
2+ and
Ca
2+ increases the apparent afﬁnity of ATP and BzATP for
the native and recombinant P2X7 receptor [11, 28, 29].
Metal ions such as Cu
2+,N i
2+,C d
2+,Z n
2+,C o
2+ inhibit
P2X7 evoked currents [30, 31]. The widely used calmod-
ulin antagonist calmidazolium, inhibits BzATP-induced
currents in HEK293 cells stably expressing the rat P2X7
receptor while, it has no effect on YO-PRO-1 uptake. This
evidence was interpreted as proof that it is possible to
dissociate the channel from pore function, and therefore
these might be two separate molecular entities [24].
The carboxyl-terminal cytoplasmic domain of P2X7 (AA
352Y595) is longer than in other members of the P2X
subtype. This domain is crucial for P2X7 pore formation,
transduction and signalling [16, 29, 32]. Allelic mutations,
leading to loss of function, have been identiﬁed both in the
human and mouse receptor. A mutation (P451L) in the
P2X7 cytoplasmic tail occurring in some mice strains
reduces the capacity of ATP to induce pore formation [33,
34]. It has been suggested that pore formation requires over
95% of the C-terminal tail of the receptor. Experiments
performed with truncated receptors expressed in HEK-293
cells and Xenopus oocytes show that truncation of the
protein at residue 581 allows only negligible inﬂux of
ethidium while, surprisingly, cells expressing a receptor
truncated at position 582 have unchanged uptake [35]. In
contrast, formation of the ionic channel occurs even in
cells expressing receptors truncated at position 380, sug-
gesting that only a limited portion of the cytosolic region is
needed for channel activity [35].
The glutamic acid 496 seems to be important for the
pore-forming activity of P2X7, and substitution of Glu
496
with Ala (E496A), occurring in the ankyrin repeat motif of
the carboxyl-terminal domain of the receptor, leads to loss
of function of the receptor in homozygous individuals and
around 50% reduction in heterozygous individuals [36].
The reversible ATP-induced permeabilization of human
erythrocytes to Rb
+,K
+ and Na
+ depends on P2X7 receptor
activation and is impaired in cells from subjects with inhe-
rited loss of function polymorphisms at amino acid
positions 307 and 496 [37]. The ﬁrst polymorphism
substitutes an uncharged glutamine for a highly positive
charged Arg
307 (R307Q) [38]. This loss of function
polymorphism likely blocks the binding of ATP to the
extracellular domain of the receptor. Another known loss
of function polymorphism to P2X7 is due to the substitu-
tion of Ile
568 with Asn (I568N) and is located in a tracking
motif in the carboxyl terminus; this polymorphism blocks
normal trafﬁcking and membrane expression of the
receptor [35, 39].
The Hill coefﬁcients obtained from the ATP dose-depen-
dency curves are consistent with multiple ATP-binding sites
[28, 40]. Studies performed with P2X7 receptors fused with
enhanced green ﬂuorescent protein (EGFP), reveal that
there are no large scale changes in P2X7 receptor density
when pore formation occurs [41].
Li and colleagues postulated a differential assembling of
the P2X7 receptor complex in diverse cell types. Experi-
ments performed in rat parotid duct and acinar cells would
indicate that while in the ﬁrst cell type, P2X7 gating is fast
and independent on cytoskeleton, in acinar cells, activation
of the receptor is slower and requires actin polymerisation
[10]. It has been suggested that the ATP-induced P2X7
pores increase or decrease by very small units [42]. It is not
known why in some cell types P2X7 expression gives rise
to the ATP-dependent pore, while in other cells (human
lymphoblastoid cells, human and rat ﬁbroblasts) the
channelYpore transition does not occur [2, 25, 43, 44].
A subject that has interested numerous authors in the last
few years is the membrane blebbing/vesiculation associat-
ed with P2X7 activation. Among other features, the
vesicles have been shown to contain active IL-1b,a n
important proinﬂammatory cytokine. P2X7 activation leads
to loss of plasma membrane and to phospholipid ﬂip. Upon
a brief stimulation with P2X7 agonists, phosphatidylserine
exposure reverses within hours, without concomitant cell
death [45]. The ROCKI kinase pathway plays a key role in
the cytoskeletal rearrangement following P2X7 activation
[46, 47].
Western blot analysis of native proteins shows that P2X7
forms multimeric complexes in rat bone marrow cells and
peritoneal macrophages, while it is present as a monomer
in brain glia or astrocyte lysates [48]. This could be due to
expression of regulatory proteins modulating the channelY
pore transition process. Different P2X7-interacting proteins
have been identiﬁed. Mass spectrometry on immuno-
precipitates showed that a complex comprising 11 proteins
interacts with the receptor: laminin a3, integrin b2, b-actin,
a-actinin, supervillin, matrix activated MAGuK (mem-
brane-associated guanylate kinase P55), heat shock proteins
70 and 90 (Hsp70, Hsp90), heat shock cognate protein 71
(Hsc71), phosphatidylinositol 4-kinase (PI4K) and receptor
protein tyrosine phosphatase-beta (RPTPb). Among those
RPTPb and Hsp90 have been proposed to functionally
modulate P2X7 [49, 50]. To isolate other potentially P2X7
related proteins the yeast two hybrid approach has also
been used, resulting in isolation of various epithelial mem-
brane protein family members (EMPs). The EMPs have
been linked to cell blebbing and in general to receptor-
mediated apoptosis [51].
Putative LPS-binding domains have been identiﬁed in
the C-terminal domain. This seems to ﬁt with the property
of P2X7 to modulate secretion of different immunomodu-
latory molecules (IL-1b, TNF-a, NO) in LPS-stimulated
macrophages. ProteinYprotein and proteinYlipid interaction
motifs within the receptor tail were also identiﬁed [52].
P2X7-derived peptides are able to bind LPS and block two
LPS-modulated intracellular events, i.e. the capacity of
activating extracellular signal-regulated kinases 1 and 2
(ERK1, ERK2) and stimulation of IkappaB-alpha degrada-
tion. In human leukaemic lymphocytes, P2X7 ion channel
activation by ATP stimulates phospholipase D (PLD)
through the inﬂux of bivalent cations [53].
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formed in the immune system, recent reports showed
expression and putative functions of the receptor also in
other cell types such as the human neuroblastoma cell line
SH-SY5Y [54], glial Mu ¨ller cells from the human retina
[55], mouse Schwann cells [56], and rat pituitary cells [57].
The presence of transcripts for the P2X7 subtype has
been detected in preparations of medulla oblongata, spinal
cord, and nodose ganglion. P2X7 protein has been found in
the presynaptic terminals in the central nervous system
[58]. The receptor is localized to the excitatory terminals in
the hippocampus and its stimulation induces the release of
glutamate and GABA [59]; primary astrocytes cultures
from rat hippocampus are also immunopositive for P2X7.
Contrasting observations have been recently published on
involvement of P2X7 in mossy ﬁber-CA3 sinaptic
responses. Activation of this receptor has been found to
depress mossy ﬁber-CA3 synaptic transmission through
activation of p38 MAP kinase [60], but BzATP-mediated
decrease of mossy ﬁber-C3 potential was shown not to be
mediated by P2X7 [61]. The authors hypothesize that
BzATP is extracellularly catabolized to Bz-adenosine and
subsequently hetero-exchanged for intracellular adenosine
that would be responsible for depressing mossy ﬁbers
potential through presynaptic A1 receptors [61]. According-
ly, Sim and colleagues failed to detect P2X7 receptor in
hippocampal neurons [62].
P2X7 receptor stimulation provides a new route for
excitatory amino acid release (L-glutamate and D-aspartate)
from murine cortical astrocytes [63]. Activation of the
receptor is also coupled to the phosphoinositide 3-kinase
(PI3K)/Akt pathway in rat cortical astrocytes and in P2X7-
expressing 1321N1 cells [64].
Death or life?
It was soon evident that extracellular ATP was a potent
permeabilizing and cytotoxic factor for macrophages.
Steinberg and Silverstein demonstrated that, upon exposure
of macrophages to high ATP concentrations, most of the
cells died and the surviving ones were insensitive to ATP-
mediated permeabilization and refractory to ATP cytotoxic
effects [14]. These ﬁndings suggested that ATP-mediated
responses were due to expression of cytotoxic receptor/s
and not to the mere perturbation of the plasma membrane
integrity by ATP [14, 21]. These observations were later
conﬁrmed by experiments performed with pharmacological
inhibitors of the receptor having different properties and
showing diverse species/speciﬁcity, i.e. periodate oxidized-
ATP (oATP), 1-[N,O-Bis(5-isoquinolinesulfonyl)-N-meth-
yl-L-tyrosyl]-4-phenylpiperazine (KN-62), and brilliant blue
G. Oxidized ATP [65], is active not only at P2X7 but also at
other P2X subtypes. KN-62 only inhibits human P2X7 [66],
while brilliant blue G is active at the murine subtype [67]. A
further proof of the existence of the receptor was given by
the demonstration that blockade of P2X7 by a speciﬁc
monoclonal antibody fully abrogated ATP-mediated cyto-
toxicity. Furthermore, cells lacking reactivity to anti-P2X7
antibodies were also resistant to the ATP permeabilizing and
cytotoxic effects [68].
P2X7 would thus be a cytotoxic receptor, capable of
killing the cell by forming membrane pores, and ATP not
just an intermediate of intracellular energy transactions but
a potent cytotoxic molecule. Since the cytotoxic effect
occurs only at high extracellular ATP concentrations,
massive release of the nucleotide due to cell damage or
lysis, or decreased activity of the ATP hydrolysing
enzymes (ecto-ATPases and ecto-nucleotidases) have to
be postulated. For example, hematopoietic precursor cells
isolated from mouse bone marrow, which express P2X7
receptors, are very sensitive to ATP and are killed by
stimulation with the nucleotide. This high sensitivity has
permitted the establishment of an efﬁcient procedure to
isolate highly puriﬁed marrow stromal cells, by deleting
hematopoietic cell precursors [69]. Elimination of P2X7-
expressing cells can also be signiﬁcantly increased by
incubating cells in the presence of a toxic agent such as
potassium thiocyanate that enters the cell membrane upon
P2X7 receptor opening [70]. This same procedure might be
helpful for the treatment of tumors of hematopoietic or
other origins.
ATP can induce cell death by either necrosis or apoptosis,
depending upon the incubation time, ATP dose and cell type
[71]. The ability of extracellular ATP to cause apoptosis of
mouse cell lines was initially documented in P-815
mastocytoma and YAC lymphoid cells, and then subse-
quently extended to mouse thymocytes [22, 72, 73]. P2X7-
expressing J774 mouse macrophages mostly die by
colloido-osmotic lysis as they quickly swell, change
refrangence, detach from the substrate and release cytoplas-
mic components. Recently, P2X7 has also been shown to
cause apoptotic death of BAC1 macrophages [74]. Mouse
microglial cell lines N9 and N13 also show condensation
of nuclei and DNA fragmentation, which are both hall-
marks of apoptosis. Furthermore, stimulation with ATP of
N9 and N13 cells induces activation of different caspases.
Caspase-1, 3 and 8 are activated and caspase substrates
such as PARP and lamin B are processed [75, 76]. Activa-
tion of casp-3 and casp-9 has been shown in human
cervical epithelial cells [77]. Triggering of P2X7 induces
phosphatidylserine externalization and membrane blebbing
[45]. These effects are mediated by P2X7 as they are
blocked by P2X7 inhibitors and are absent in P2X7-less
cells. Increased P2X7 expression has been found in the
peri-infarct region in the rat brain cortex after cerebral
artery occlusion; augmented P2X7 protein levels were de-
tected in microglia, neurons and apoptotic cells [78].
Stimulation of P2X7 receptor induces release of tumor
necrosis factor alpha (TNF-a) from microglia [79].
Sugiyama and colleagues reported that in pericyte-
containing retinal microvessels, activation of P2Y4 recep-
tors by UTP prevented P2X7 pores from forming. These
data would point to a cross-talk between the P2X and P2Y
subtypes in inducing/preventing cell death. They also
showed that maximal activation of P2X7 resulted in
voltage-dependent calcium channels (VDCCs) opening,
exacerbating the death process [80].
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ADP-ribosylation. It has been shown that exposure of T
lymphocytes to NAD, the substrate of ART-2, causes P2X7
receptor ADP-ribosylation and P2X7-dependent apoptosis
characterized by exposure of phosphatidylserine [81],
shedding of CD62L, propidium iodide uptake and cell
shrinkage [82, 83].
Human ﬁbroblasts from diabetic patients show enhanced
P2X7-mediated responses e.g. increased shape change,
microvesiculation, increased IL-6 secretion and accelerated
apoptosis [84]. Lymphocytes from type 1 diabetic (NOD)
mice show an increased apoptosis upon stimulation of the
P2X7 receptor, that also results in an augmented shedding
of the lymphocyte homing receptor CD62L [85].
Purinoceptors can also be activated by spontaneous or
stimulated ATP release through an autocrine or paracrine
loop. A basal ATP release occurs in vitro, thus providing a
chronic stimulation of P2 receptors. Murine macrophages
expressing high levels of P2X7 show an unusually high rate
of spontaneous cell death that can be signiﬁcantly reduced
by inhibiting P2X7, or by incubation of the cells in the
presence of the ATP-hydrolyzing enzyme apyrase, suggest-
ing that the P2X7 receptor is activated by constitutively
released ATP [86].
Extracellular ATP induces apoptosis of human periph-
eral monocytes infected with Mycobacterium bovis (bacil-
lus Calmette Guerin, BCG) as demonstrated by DNA
fragmentation and nuclear condensation. Interestingly and
more importantly, ATP also induces swelling of the BCG-
containing vacuoles and reduces BCG viability [87]. Pore
formation upon P2X7 receptor stimulation is responsible
for induction of cell death of BCG-infected human macro-
phages. Triggering of P2X7 receptor also induces death of
the intracellular bacteria, at variance with CD95 or
complement activated cell death that only kills macro-
phages [88]. The crucial step in the killing of the intra-
cellular parasite is fusion of the parasite-containing
phagosomes with intracellular lysosomes [89].
Li and colleagues showed that heterogeneity in cell
donors with respect to ATP responsiveness could depend
on p2x7 polymorphisms and suggested an association
between a single-nucleotide polymorphism in the P2X7
promoter (position j762) and infection by Mycobacterium
tuberculosis [90]. Another P2X7 polymorphism, this time
situated in the coding region (A/C 1531), has been
associated with the inability of macrophages to kill myco-
bacteria [91]. A putative role for P2X7 during infection has
also been hypothesized since two inﬂammatory cytokines
such as interferon-g (IFN-g) and tumor necrosis factor-a
(TNF-a) upregulate P2X7 expression [92Y94].
Extracellular ATP is a powerful stimulus for IL-1b
secretion [95]. Endotoxin (LPS) induced IL-1b release is in
fact a very inefﬁcient process, since it is slow and leads to
secretion of a modest amount of the cytokine. Addition of
extracellular ATP to endotoxin-primed macrophages or
microglial cells causes a fast release of a large quantity of
processed IL-1b. The process is dependent on P2X7
stimulation and ATP is an efﬁcient stimulus for IL-1b
secretion only if cells have been previously primed with
LPS, pointing to a role for the nucleotide in accelerating
the proteolytic maturation of the cytokine [76, 96Y98]. This
hypothesis was then validated by studies performed in
p2x7
j/j mice. In peritoneal macrophages obtained from
these animals pro-IL-1b is not processed and externalised
in response to ATP. In contrast to what is observed in
cells from wild type mice. Injection of ATP in endotoxin
treated p2x7
j/j animals also failed to increase IL-1b pro-
duction [99].
p2x7
j/j mice are also less prone to develop cartilage le-
sions, loss of proteoglycan content, and presence of collagen
degradation products [100].
P2X7 receptor in cell growth and tumor models
In apparent contrast with the role of P2X7 receptor in
necrosis and apoptosis, an increasing number of reports has
also correlated this protein with increased cell proliferation
and tumor transformation. The ﬁrst cellular model in which
ar o l ef o rP 2 X 7 in cell growth was suggested were T lym-
phocytes [101].
In human peripheral blood lymphocytes (PBL) and T
CD4
+ and CD8
+ subpopulations, ATP increases mitogenic
activity via the P2X7 receptor, when co-applied with anti-
CD3 antibodies, phytohaemoagglutinin (PHA) or heterol-
ogous leucocytes, all stimuli that mimic TCR/MHC activation
[101]. Extracellular nucleotides were known to stimulate
proliferation through activation of P2Y receptors, the
novelty of this study was to attribute a proliferative activity
to a pro-apoptotic receptor. A further step in the analysis of
the possible involvement of the receptor in promoting
proliferation, was made by analysing the behaviour of
human B lymphoid cells stably transfected with a P2X7
receptor cDNA [102]. In contrast to wild type cells, the
P2X7 transfectants acquired the ability to survive and
proliferate in the absence of serum, a hallmark of
cancerous cells. Proliferation is likely supported by an
autocrine/paracrine stimulation of released ATP. Indeed,
P2X7-expressing cells release an amount of ATP that is
four-fold larger than in control cells. Moreover incubation
of the P2X7 transfectants with the ATP-hydrolyzing
enzyme apyrase or pre-treatment with oxidized ATP
(oATP) abrogates proliferation [101]. Recently, Budagian
and coworkers dissected the signalling pathways responsi-
ble for P2X7 effects in lymphocytes, demonstrating that in
Jurkat cells, a human T lymphocyte cell line, P2X7
activation results in phosphorylation and activation of
p56
lck [103]. p56
lck is a lymphoid speciﬁc tyrosine kinase
mediating the initial events of TCR/CD3 signalling leading
to mitogenic activation of T lymphocytes. Active p56
lck
phosphorylates the TCR allowing the docking of other
kinases such as Zap-70 and Syk to its complex; p56
lck also
stimulates MAP kinases. The P2X7 dependent activation of
p56
lck may offer an explanation for the proliferation-
promoting effects of ATP on CD3 activated T lymphocytes
[101]. Activation of P2X7 has been shown to be able to
trigger the signalling pathway of mitogen-activated MAPK/
ERK kinases, that has been extensively investigated in
222 E. Adinolﬁ et al.different cell types such as mouse macrophages and micro-
glia, human astrocytoma and rat parotid ancinar salivary
cells [74, 104Y106]. MAP kinases are known to promote
cell growth and proliferation by inducing de novo synthesis
of pyrimidine nucleotides in the nucleus [107]. They also
activate transcription factors, triggering expression of early
response genes coding for growth-promoting proteins
[108].
Chronic lymphocytic leukaemia B lymphocytes were
one of the ﬁrst cellular models in which P2X7 like activity
was investigated [109, 110] and are currently a hot ﬁeld of
investigation in view of the possible application in the
prognosis and therapy of this disease [111Y113]. B chronic
lymphocytic leukaemia (B-CLL) is the most common leu-
kaemia in the western world, and despite a known familial
incidence and higher percentage of male individuals among
patients, it has not been associated with a speciﬁc genetic
Fhallmark_ [114]. Recently it has been shown that P2X7R
expression and function is higher in CLL patients with the
aggressive variant of the disease, compared to those
affected by the indolent form [111]. Patients affected by
the aggressive form showed accordingly higher resting
calcium levels and ATP evoked calcium inﬂux as well as
higher sensitivity to ATP-mediated cytotoxicity. The pro-
posed model predicts that a tonic, low activation of P2X7
receptor will lead to an increased proliferation, while an
acute stimulation with high concentrations of nucleotide
causes death of tumor lymphocytes (Figure 1) [111].
More controversial at the moment is the association of a
loss of function P2X7 polymorphism with B-CLL inci-
dence and progression. This polymorphism (1513AYC)
codes for glutamic acid to alanine at amino acid position
496 in the C-terminal tail of the receptor [36]. It was ﬁrst
identiﬁed in normal subjects in which it caused a reduced
ATP-mediated barium and ethidium uptake. Subsequently,
this mutation was proposed as a prognostic marker in B
cells, but no consensus has been reached as yet on this
matter [115Y118].
Besides B chronic lymphocytic leukaemia, several other
tumors show an altered expression of the P2X7 receptor.
For example, non-melanoma skin cancers express this re-
ceptor and die upon massive application of ATP or BzATP
[119]. In this case the receptor seems to be associated with
cells undergoing apoptosis as it colocalises with TUNEL
and active caspase-3 staining [119]. For other widely dif-
fused neoplasia, such as prostate and breast cancer, the
expression of P2X7R has been immunologically detected
speciﬁcally in transformed cells [6, 120]. One hundred
fourteen out of 116 prostate cancer biopsies stained
positively for the P2X7 receptor and also cells well distinct
from the tumor show expression of the receptor along with
tumor progression [120]. Likewise, all cases of in situ
lobular and ductal carcinoma showed intense P2X7
labelling in the nuclei and cytoplasm, while more aggres-
sive forms tended to present the receptor at the cell surface
[6]. The authors of these studies infer that the expression of
the P2X7 receptor could be an attempt of cancer cells
to undergo apoptosis, that fails because the receptor might
be nonfunctional. However no functional studies were
performed.
This increasing number of reports suggests that applica-
tion of nucleotide-derived drugs, able to modulate P2X7
receptor functions, might be useful in tumour therapy
[121]. To this aim, development of allosteric modulators of
the P2X7 receptor that potentiate the effect of ATP might
be an alternative approach to decrease ATP dose and
therefore reduce the side effects of ATP break-down
products or of ATP itself.
The anti-inﬂammatory drug tenidap synergises with
extracellular ATP for activation of the P2X7 receptor, by
increasing the afﬁnity of the P2X7 for ATP [122]. The
natural antibiotic polymyxin B (PMB) is a well-known
agent binding and neutralizing bacterial endotoxin. It has
recently been shown that PMB ampliﬁes ATP-induced
responses by acting at both recombinant or natively
expressed P2X7R in several cell models [123]. Another
possible therapeutical approach to neoplasias could be the
use of P2X7 antagonists to counteract the proliferative
advantage conferred by the receptor to the transformed
cells. Several P2X7 receptors antagonist/blockers have
been identiﬁed but none of them is selective [20]. Brilliant
blue G [67] and KN-62 display a good potency, the latest
compound is also a CaM kinase II (calciumYcalmodulin
dependent protein kinase type 2) inhibitor. There have been
different attempts to obtain KN-62 analogues [124], more
active and speciﬁc for P2X7 [125Y127]. The benzophenan-
thridine alkaloid chelerythrine, a potent PKC inhibitor, has
Figure 1. Low tonic or massive stimulation with ATP of P2X7-
expressing cells causes a transient or a prolonged opening of the
receptor-pore, respectively; this in-turn induces a modest or high
intracellular Ca
2+ concentration increase. Although changes in calcium
are unlikely to be solely responsible for the duality in P2X7-mediated
effects, they represent physiological triggering points in diverse upstream
and downstream signalling processes, activating different cell functions
and responses.
P2X7 receptor: Death or life? 223a noncompetitive inhibitory action on the P2X7 receptor
expressed by human B lymphocytes [128]. Quite recently
new adamantate amide antagonists, which show a high
potency at P2X7 receptor, have been isolated by two
groups at Astra Zeneca [129, 130]. Further studies on this
direction could provide useful tools to better understand
the physiological functions of P2X7 not only in tumour
models but also in other cell types such as immune and
epithelial cells.
Conclusions
In conclusion the P2X7 receptor seems to play a role in
both cell death and survival. These two opposite functions
are only apparently contradictory as they may depend on
the speciﬁc intracellular pathway activated by P2X7 at
different points or in diverse phases of the cell cycle. Low
tonic stimulation by ATP is postulated to produce a low-
level activation of P2X7 that supports growth. On the
contrary, massive P2X7 stimulation would lead to cell
death (Figure 1). In this view, it would be of great interest
to measure ATP concentration at cell membrane.
Pro-apoptotic, pro-inﬂammatory receptors acting in
some cases as growth-promoting tumorigenic proteins are
not novel: TNF-a receptor (p55) for example, is known for
both its cytotoxic activity and for promoting cancer cell
growth [131].
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